©The Author(s) 2023.
World J Gastroenterol. Feb 14, 2023; 29(6): 1076-1089
Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.1076
Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.1076
Table 1 Baseline characteristics of patients in the training and validation cohort
| Characteristics | Train cohort | Validation cohort | ||
| nEGVB (n = 87) | EGVB (n = 62) | nEGVB (n = 36) | EGVB (n = 26) | |
| Sex (Male) | 54 (62.1%) | 40 (64.5%) | 21 (58.3%) | 16 (61.5%) |
| Age(yr) | 55.0 (36.0, 83.0) | 53.0 (15.0, 79.0) | 52.0 (10.8) | 52.9 (12.5) |
| Etiology | ||||
| HBV | 58 (66.7%) | 38 (61.3%) | 19 (52.8%) | 16 (61.5%) |
| HCV | 5 (5.7%) | 6 (9.7%) | 3 (8.3%) | 1 (3.8%) |
| Alcohol | 4 (4.6%) | 7 (11.3%) | 3 (8.3%) | 3 (11.5%) |
| Others | 20 (23.0%) | 11 (17.7%) | 11 (30.6%) | 6 (23.1%) |
| Portal vein thrombosis | 5 (5.7%) | 21 (33.9%) | 1 (2.8%) | 8 (30.8%) |
| Shunt | 21 (24.1%) | 21 (33.9%) | 14(38.9%) | 9 (34.6%) |
| HE | 1 (1.1%) | 6 (9.7%) | 0 (0%) | 2 (7.7%) |
| Ascites | ||||
| 0 | 40 (46.0%) | 9 (14.5%) | 13 (36.1%) | 6 (23.1%) |
| 1 | 31 (35.6%) | 45 (72.6%) | 22 (61.1%) | 17 (65.4%) |
| 2 | 5 (5.7%) | 6 (9.7%) | 1 (2.8%) | 2 (7.7%) |
| 3 | 11 (12.6%) | 2 (3.2%) | 0 (0%) | 1 (3.8%) |
| Child-Pugh score | ||||
| A | 33 (37.9%) | 16 (25.8%) | 15 (41.7%) | 9 (34.6%) |
| B | 47 (54.0%) | 38 (61.3%) | 17 (47.2%) | 14 (53.8%) |
| C | 7 (8.0%) | 8 (12.9%) | 4 (11.1%) | 3 (11.5%) |
| PLT (109/L) | 60.0 (17.0, 186) | 72.5 (21.0, 245) | 53.0 (16.0, 192) | 60.0 (26.0, 208) |
| PT (s) | 15.6 (12.4, 24.9) | 16.1 (11.7, 26.8) | 16.1 (3.30, 22.3) | 17.1 (14.1, 31.6) |
| APTT (s) | 39.7 (29.5, 57.3) | 38.9 (30.1, 53.1) | 41.5 (34.2, 51.0) | 38.2 (30.7, 63.6) |
| INR | 1.22 (0.92, 2.18) | 1.28 (0.85, 2.51) | 1.29 (0.98, 1.95) | 1.39 (1.10, 3.00) |
| Fib (g/L) | 2.19 (0.75, 6.09) | 1.78 (0.60, 5.78) | 2.11 (0.489) | 1.80 (0.628) |
| Albumin (g/L) | 34.1 (18.4, 46.3) | 32.3 (21.3, 45.9) | 33.6 (6.36) | 30.8 (5.28) |
| Tbil (μmol/L) | 21.9 (2.20, 366) | 16.9 (3.60, 93.0) | 23.5 (6.40, 414) | 18.5 (7.00, 76.1) |
| DBil (μmol /L) | 9.80 (0.90, 276) | 8.05 (1.90, 65.9) | 10.8 (2.30, 306) | 8.70 (2.70, 38.5) |
| Prealbumin (mg/L) | 90.0 (12.0, 220) | 97.5 (18.0, 246) | 85.0 (9.00, 268) | 83.5 (18.0, 221) |
| ALT (U/L) | 36.0 (7.00, 345) | 23.0 (10.0, 85.0) | 41.0 (14.0, 337) | 22.5 (10.0, 107) |
| AST (U/L) | 47.0 (15.0, 330) | 29.5 (11.0, 92.0) | 48.0 (23.0, 319) | 25.5 (17.0, 121) |
| SL (mm) | 130 (89.1, 206) | 142 (78.8, 200) | 143 (98.7, 199) | 139 (109, 205) |
| SD (mm) | 144 (82.0, 235) | 157 (68.8, 299) | 152 (86.0, 239) | 174 (109, 222) |
| ST (mm) | 45.1 (9.22) | 52.5 (11.1) | 48.3 (30.5, 84.5) | 55.2 (29.9, 64.8) |
- Citation: Luo R, Gao J, Gan W, Xie WB. Clinical-radiomics nomogram for predicting esophagogastric variceal bleeding risk noninvasively in patients with cirrhosis. World J Gastroenterol 2023; 29(6): 1076-1089
- URL: https://www.wjgnet.com/1007-9327/full/v29/i6/1076.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i6.1076